Preventing heart issues in elderly cancer patients
Cardiotoxicity in the Elderly. Comparative Clinical Trial Between Primary Versus Secondary Cardiovascular Prevention Strategies
NA · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León · NCT03711110
This study is testing whether close heart monitoring and teamwork among doctors can help older cancer patients avoid heart problems and live longer compared to standard care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 514 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (other) |
| Locations | 14 sites (Santiago de Compostela, A Coruña and 13 other locations) |
| Trial ID | NCT03711110 on ClinicalTrials.gov |
What this trial studies
The CARTIER study is a randomized, multicenter clinical trial aimed at comparing two strategies for preventing cardiotoxicity in elderly cancer patients undergoing anti-tumoral treatment. It evaluates the effectiveness of intensive cardiovascular monitoring and multidisciplinary management against the current standard practice, which lacks routine monitoring. The primary goal is to determine if the proactive approach can reduce all-cause mortality compared to conventional care. Secondary objectives include assessing the impact on cardiovascular and oncological mortality rates.
Who should consider this trial
Good fit: Ideal candidates are elderly patients over 65 years old with specific types of cancer and an expected survival of more than one year.
Not a fit: Patients currently enrolled in other clinical trials that interfere with the CARTIER follow-up protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce mortality rates in elderly cancer patients by improving cardiotoxicity management.
How similar studies have performed: Other studies have shown promise in similar approaches to managing cardiotoxicity in cancer patients, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> 65 years old * Expected survival \>1 year * Colon cancer, breast cancer, lymphoma, chronic lymphoma leukemia, chronic myeloid leukemia, myeloma * Signature on the informed consent Exclusion Criteria: * Patients included in clinical trials will be excluded if they interfere with the CARTIER follow-up protocol. If they do not interfere they can be included * Patients who had received previous potentially cardiotoxic anticancer treatment
Where this trial is running
Santiago de Compostela, A Coruña and 13 other locations
- Hospital Clínico Universitario de Santiago de Compostela — Santiago de Compostela, A Coruña, Spain (NOT_YET_RECRUITING)
- Hospital de Galdakao-Usansolo — Galdakao, Vizcaya, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Vall d´Hebron — Barcelona, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Reina Sofía — Córdoba, Spain (NOT_YET_RECRUITING)
- Hospital Universitario de La Princesa — Madrid, Spain (NOT_YET_RECRUITING)
- Hospital G. Universitario Gregorio Marañón — Madrid, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Ramón y Cajal — Madrid, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Fundación Jiménez Díaz — Madrid, Spain (NOT_YET_RECRUITING)
- Hospital Universitario 12 de Octubre — Madrid, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Puerta de Hierro — Madrid, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Virgen de la Victoria — Málaga, Spain (NOT_YET_RECRUITING)
- Complejo Asistencial Universitario de Salamanca — Salamanca, Spain (RECRUITING)
- Hospital Universitario Virgen del Rocío — Seville, Spain (NOT_YET_RECRUITING)
- Hospital Universitario Río Hortega — Valladolid, Spain (NOT_YET_RECRUITING)
Study contacts
- Study coordinator: Pedro L Sánchez, Ph. D.
- Email: plsanchez@saludcastillayleon.es
- Phone: 923 291100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Elderly, Antineoplastic Agents, Cardiotoxicity, Antineoplastic agents, Cardiovascular monitoring, Cardioprotection, Cardio-oncology